MSC 2.0: Turning Stem Cells into Programmable Cancer Delivery Vehicles
- Atlantis Global Support
- Aug 10
- 2 min read
How can mesenchymal stem cells move beyond conventional regenerative medicine and become programmable therapeutic vehicles?
In a recent episode of the Smart Biotech Scientist Podcast, Dr Jun Yung Woo, Co-Founder of AGEM Bio, shared his journey in developing the next generation of engineered mesenchymal stem cells — a concept he describes as MSC 2.0.
The conversation explores not only the science behind engineered MSCs, but also an important question facing the cell and gene therapy field:
How do we turn promising laboratory discoveries into therapies that can eventually reach patients?
Rethinking the Potential of MSCs
MSCs are widely studied for their regenerative and immunomodulatory properties. Dr Woo’s work takes this one step further by exploring how MSCs can be engineered as programmable therapeutic delivery vehicles.
AGEM Bio’s approach combines the natural ability of MSCs to respond to inflammatory and tumour-associated environments with engineered therapeutic functions.
In the podcast, Dr Woo discusses the development of this platform, including the importance of understanding cell biology before focusing on scale-up.
For cell therapies, producing more cells does not necessarily mean producing a better therapeutic product. Expansion, engineering, cryopreservation and manufacturing processes can all influence how cells behave.
This makes bioprocess development an integral part of the therapy itself.
From Engineering Cells to Treating Cancer
The discussion also explores AGEM Bio’s work in oncology, where engineered MSCs are being developed to carry therapeutic payloads directly into tumour environments.
Rather than relying only on systemic delivery, the MSC acts as a living therapeutic vehicle — potentially localising treatment closer to the disease site.
Dr Woo also shares observations from compassionate veterinary cancer cases and discusses how these experiences provided additional insight beyond conventional laboratory models.
While such cases do not replace controlled clinical trials, they can help researchers understand how an experimental therapy behaves in naturally occurring disease and build confidence for the next stage of development.
The conversation ultimately highlights that successful cell therapy translation requires more than a promising mechanism. It requires reproducible manufacturing, clinical collaboration, appropriate models and a clear pathway towards clinical evaluation.
Supporting the Journey from Bench to Bedside
Dr Woo’s podcast conversation is part of a broader journey that Interstemcell has been privileged to support.
In 2026, we invited Dr Woo to the TISTR International Conference in Thailand to share his work on MSC 2.0 and connect with researchers, clinicians and industry partners across the region.
His team has also published a multisite proof-of-concept study evaluating off-the-shelf engineered MSCs for targeted hepatocellular carcinoma treatment, including important translational considerations such as cryopreservation, freeze-thaw recovery and international cold-chain transportation.
These initiatives reflect Interstemcell’s broader commitment to advancing the cell and gene therapy ecosystem through international scientific exchange and collaboration — helping promising technologies build the evidence, partnerships and confidence needed to progress from bench research towards clinical translation.
Hear the Full Conversation
From MSC biology and cell engineering to cancer therapy, manufacturing and the challenges of clinical translation, Dr Woo shares the story behind MSC 2.0 in the full interview.
Comments